We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.80 | 1.63% | 50.03 | 49.23 | 50.80 | 50.37 | 48.85 | 49.17 | 1,363,472 | 01:00:00 |
From May 2019 to May 2024
By Inti Landauro
PARIS--The U.S. Food and Drug Administration is to undertake a priority review of a treatment for atopic dermatitis, a chronic inflammatory skin disease, according to pharmaceutical firms Sanofi SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) which make the drug.
The two companies had said in June that a series of trials showed the treatment, known as dupilumab, combined with topical corticosteroids significantly improved the condition of a group of patients suffering from atopic dermatitis.
Back in 2014, the FDA had granted "breakthrough therapy" designation to dupilumab.
Large pharmaceutical companies like Sanofi are rushing to get new drugs to market to offset falling revenues from top-selling drugs whose patents recently expired.
-Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
September 26, 2016 01:48 ET (05:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
